Chemo-immunotherapy sequential with radiotherapy in advanced or metastatic esophageal squamous cell carcinoma
Chemo-immunotherapy followed by radiotherapy for residual tumors and maintenance sintilimab, demonstrated high response rates, prolonged PFS, and tolerable toxicity as a first-line treatment for patients with advanced or metastatic esophageal squamous-cell carcinoma.
Authors
- Youxin Ji (ORCID: https://orcid.org/0000-0003-2303-8784)
- Xiang Y. Han (ORCID: https://orcid.org/0000-0001-8472-0870)
- Yunhong You
- Keke Nie (ORCID: https://orcid.org/0000-0003-2895-4730)
- Qiuyu Hou
- Ling Zhang (ORCID: https://orcid.org/0000-0002-8343-2719)
- Zhi-Mei Zhao
- Xiuhui Guo
- Zhongfa Zhang
- Yuchao Niu
- Xiajuan Xu
Institutions
- Qingdao University (CN)
- Affiliated Hospital of Qingdao University (CN)
- Qingdao Eighth People's Hospital (CN)
Publication Details
- Journal
- Future Science OA
- Published
- 2025-07-16
- DOI
- https://doi.org/10.1080/20565623.2025.2527497
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00